A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

Speciality: Oncology

Description:

A warm welcome to all the medical professionals in this engaging session, continuing our deep dive into EGFR Mutation Positive Non-Small Cell Lung Cancer. The management of EGFR-mutated non-small cell lung cancer (NSCLC) has been revolutionized by the discovery of specific epidermal growth factor receptor (EGFR) mutations and the subsequent development of targeted therapies. While first and second-generation EGFR tyrosine kinase inhibitors (TKIs) marked significant improvements over traditional chemotherapy, leading to better response rates, progression-free survival, and quality of life, the landscape continues to evolve rapidly.

Recent advancements, particularly with third-generation EGFR TKIs like osimertinib, have further refined frontline treatment strategies, offering superior efficacy and improved central nervous system (CNS) penetration. Furthermore, the emerging role of combination therapies, such as osimertinib with chemotherapy, and novel agents like bispecific antibodies (e.g., amivantamab) are pushing the boundaries of treatment outcomes. This session, led by Dr. Ghanashyam Biswas, aims to explore these latest developments through case discussions, highlighting best practices in tailoring treatment for individual patients based on their molecular profile and disease characteristics.

Therefore, join us for a comprehensive understanding of the latest strategies and evolving evidence in the treatment of EGFR mutation-positive NSCLC. Participate in this insightful webinar, acquire valuable knowledge from shared case discussions, and continue to follow Hidoc for more such enriching educational sessions.

See More Webinars @ Hidoc Webinars